Overview
McDermott Will & Emery advised DBV Technologies, a clinical-stage biopharmaceutical company, on a private placement financing (PIPE) for an aggregate amount of USD194 million from the issuance and subscription of ordinary shares and pre-funded warrants.
This financing is in line with previous fundraisings in recent years and more recently in May 2022 in connection with the implementation of an at-the-market programme (ATM programme), with which McDermott Will & Emery had also assisted the company.
Goldman Sachs Bank Europe SE and SVB Securities LLC acted as placement agents for the PIPE financing.
The McDermott team that advised DBV was composed of Bertrand Delafaye and Emmanuelle Trombe, partners, and Lucie Martin, Ludivine Rabreau and Claire Chabat, associates, on all legal aspects of the transaction and Côme de Saint-Vincent, Counsel, on tax aspects.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
